Drugs / BMS-741672
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00699790 | Feb → Dec 2009 | type 2 diabetes mellitus | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 2 | NCT00683423 | Jul 2008 → Jan 2009 | neuropathy, painful | Bristol-Myers Squibb | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BMS-741672 | “a CCR2 antagonist (BMS-741672) improves glucose homeostasis in drug-naive type 2 diabetic patients” NCT00699790 ↗ |
| Action | Inhibit | “CCR2 antagonist” NCT00699790 ↗ |
| Modality | Small molecule | — CHEMBL4457723 ↗ |
| Route | Oral | “Tablets, Oral, 100 mg, once daily, 3 weeks” NCT00683423 ↗ |
| Target | CCR2 | “CCR2 antagonist” NCT00699790 ↗ |